One of the global leaders in animal health, Elanco will invest $130 million to expand the production capacity of its biologics manufacturing facility in Kansas, USA. Elanco pointed out that the expansion bolsters its commitment to innovation in monoclonal antibody (mAb) products.
Elanco Animal Health Incorporated has announced a 25,000-square-foot expansion of its biologics manufacturing facility in Elwood, Kansas, USA. The expected $130 million investment through 2026 will enable further growth of the company’s monoclonal antibody (mAb) platform, building on the robust expertise already present at this facility, the company explains.
“Expanding the capabilities at our Elwood manufacturing site is a critical step toward executing the most exciting pipeline in Elanco’s 70-year history,” says Grace McArdle, Executive Vice President, Manufacturing and Quality for Elanco. “In partnership with our Elanco R&D colleagues, this site plays a key role in delivering solutions that are transforming the way veterinarians and pet owners care for the world’s animals. We appreciate the commitment of the State of Kansas, Doniphan County and the City of Elwood to help pets live longer, healthier, more active lives.”
Currently, Elanco’s Elwood facility plays a crucial role in manufacturing and shipping its Canine Parvovirus Monoclonal Antibody (CPMA), according to the company’s statement. Parvovirus is estimated to affect more than 330,000 puppies a year1 with a mortality rate as high as high as 91% if left untreated2. CPMA is the first and only USDA conditionally approved, targeted treatment for canine parvovirus. This is Elanco’s first mAb in the market with plans for future innovation in this technology platform.
The animal health sector is increasingly focusing on antibody-based therapies, drawing insights from advancements in human health. These therapies are recognized for their effectiveness and the potential for faster resolution of clinical signs or severe disease. They will be fundamental in enhancing the quality of life for pets and strengthening the human-animal bond.
“Elanco’s R&D strategy is centered around a consistent flow of high-impact innovation in key markets. In Animal Health, we believe monoclonals have untapped potential, and Elanco is one of only two companies within our industry that have monoclonals on the market today. We believe the monoclonal platform is a key path to deliver these new, high impact innovations – and today’s news about our investment to expand the Elwood site creates the footprint we need to scale up and manufacture our future innovation portfolio,” expresses Dr. Ellen de Brabander, Executive Vice President of Research & Development.
Elanco expects its next monoclonal antibody, a future potential product in canine dermatology, in 2025. The Elwood facility will play an essential role in producing supply.
“Driving innovation that enhances animal health – particularly emphasizing the crucial role pets have in our lives – is vital,” points out Bobby Modi, Executive Vice President, U.S. Pet Health. “This expansion enables our teams to deliver even more transformative solutions for pets and their families. With pet life expectancy increasing, there is an ever greater need to evolve and develop new, innovative technologies that keep our pets healthy and active longer.”
In addition to doubling production capacity the manufacturing facility with upstream and downstream processing equipment, the project will also feature a new pilot plant to accelerate product pipeline delivery, a new quality control laboratory, as well as additional support spaces
- Elanco Animal Health. Data on File.
- Venn, E.C. et al. Evaluation of an outpatient protocol in the treatment of canine parvoviral enteritis. Journal of Veterinary Emergency and Critical Care. 27(1) 2017, 52-65. doi: 10.1111/vec.12561.
